Cargando…
Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: Comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex
Mifepristone (RU486), a synthetic steroid compound used as an abortifacient drug, has received considerable attention to its anticancer activity recently. To explore the possibility of using mifepristone as a cancer metastasis chemopreventive, we performed a systems pharmacology analysis of mifepris...
Autores principales: | Yu, Suhong, Yang, Xingtian, Zhu, Yewei, Xie, Fangwei, Lu, Yusheng, Yu, Ting, Yan, Cuicui, Shao, Jingwei, Gao, Yu, Mo, Fan, Cai, Guoneng, Sinko, Patrick J., Jia, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297966/ https://www.ncbi.nlm.nih.gov/pubmed/25597938 http://dx.doi.org/10.1038/srep07830 |
Ejemplares similares
-
Determination of Mifepristone (RU-486) and Its Metabolites in Maternal Blood Sample after Pharmacological Abortion
por: Szpot, Paweł, et al.
Publicado: (2022) -
RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion
por: Yu, Suhong, et al.
Publicado: (2019) -
Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention
por: Yu, Suhong, et al.
Publicado: (2016) -
Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications
por: Gallagher, Peter, et al.
Publicado: (2006) -
A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri
por: Mukherjee, Sucheta, et al.
Publicado: (2011)